<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Results</title>
    <link rel="stylesheet" href="./lib/css/styles.css">
</head>
<body class="results">
<p><strong>Chronic liver disease. Diagnosis and staging of liver fibrosis. Initial imaging</strong></p>
<p><a href="https://acsearch.acr.org/docs/3098416/Narrative/">https://acsearch.acr.org/docs/3098416/Narrative/</a></p>
<p><strong>&nbsp;</strong></p>
<p><strong>US shear wave elastography abdomen and &nbsp;MR elastography abdomen is usually appropriate.</strong></p>
<p><strong>MRI abdomen without and with IV contrast, CT abdomen with IV contrast multiphase, MRI abdomen without and with hepatobiliary contrast, MRI abdomen without IV contrast, US abdomen, US duplex Doppler abdomen, US abdomen with IV contrast may be appropriate. </strong></p>
<p><strong>CT abdomen without and with IV contrast, CT abdomen without IV contrast , FDG-PET/CT skull base to&nbsp; mid-thigh is usually not appropriate.</strong></p>
<p><strong>&nbsp;</strong></p>
<p>Patients with chronic liver disease can present with findings of frank cirrhosis and portal hypertension, including jaundice and ascites. However, in many patients, the severity of liver disease is not apparent based on clinical or laboratory findings. In general, imaging can be helpful to confirm the presence of cirrhosis based on morphological&nbsp; features. For patients without cirrhosis, determining the presence and severity of earlier stages of liver fibrosis may help guide management.A variety of morphologic changes that accompany cirrhosis can be assessed on CT, MRI, and US. These include liver surface nodularity, right lobe atrophy, caudate lobe hypertrophy, the right hepatic posterior &ldquo;notch,&rdquo; and others[15-18]. However, even in aggregate, the sensitivity of these features for the diagnosis of cirrhosis and noncirrhotic fibrosis&nbsp; is&nbsp; too&nbsp; low&nbsp; for&nbsp; excluding&nbsp; hepatic&nbsp; fibrosis.&nbsp; Recently,&nbsp; quantitative&nbsp; methods&nbsp; for&nbsp; assessing&nbsp; liver&nbsp; surface nodularity have been developed, but are still early in development and are not yet considered well-validated for this application [19,20].</p>
<p><strong>CT Abdomen</strong></p>
<p>Noncontrast CT has limited utility in the assessment of hepatic fibrosis because it&nbsp;&nbsp; relies on the demonstration of gross&nbsp; structural&nbsp; changes,&nbsp; which&nbsp; are typically&nbsp; not&nbsp; present&nbsp; until very&nbsp; advanced&nbsp; stages of&nbsp; the&nbsp; disease.&nbsp; Contrast-enhanced CT can be more useful because it&nbsp;&nbsp; can demonstrate parenchymal heterogeneity and enhancement of lattice-like macroscopic bands of fibrosis throughout the hepatic parenchyma [21,22]. CT perfusion has been described forthe&nbsp; assessment&nbsp; of&nbsp; hepatic fibrosis&nbsp; and&nbsp; cirrhosis,&nbsp; predominantly&nbsp; relying&nbsp; on&nbsp; increased&nbsp; proportion of&nbsp; arterial&nbsp; blood supply&nbsp; to&nbsp; the&nbsp; liver&nbsp; as fibrosis&nbsp; progresses [23].&nbsp; However,&nbsp; this&nbsp; methodology is&nbsp; highly technique&nbsp; dependent&nbsp; andrequires substantial postprocessing and therefore is not considered a clinical standard method for establishing thediagnosis of cirrhosis. There is no relevant literature that demonstrates incremental value of combining noncontrastwith contrast-enhanced CT for this application.</p>
<p><strong>FDG-PET/CT Skull Base to Mid-Thigh</strong></p>
<p>Fluorine-18-2-fluoro-2 -deoxy-D-glucose (FDG)-PET is not a useful test for detecting liver fibrosis. Data are limitedregarding its utility, and no advantage over alternative imaging or serum tests has been demonstrated.</p>
<p><strong>MR Elastography Abdomen</strong></p>
<p>MR elastography is currently the most accurate imaging modality for the diagnosis and staging of hepatic fibrosis[24,25].&nbsp; MR&nbsp; elastography&nbsp; compares favorably&nbsp; with&nbsp; US&nbsp; shear&nbsp; wave&nbsp; elastography&nbsp; (SWE),&nbsp; in&nbsp; part,&nbsp; because&nbsp; ofimproved performance in patients with obesity [26]. MR elastography does have limitations in patients with hepaticiron deposition and patients imaged at 3T due to susceptibility artifacts, which can result in undersampling of theliver&nbsp; or&nbsp; nondiagnostic&nbsp; evaluations.&nbsp; Stiffness measurement&nbsp; may&nbsp; also&nbsp; be&nbsp; confounded by&nbsp; parenchymal&nbsp; edema,inflammation, cholestasis, cardiogenic hepatic congestion, recent meal, and other factors [27].</p>
<p>&nbsp;</p>
<p><strong>MRI Abdomen</strong></p>
<p>Conventional&nbsp; MRI can&nbsp; be&nbsp; used&nbsp; to&nbsp; assess the&nbsp; same&nbsp; structural&nbsp; changes as those&nbsp; visualized&nbsp; on&nbsp; CT,&nbsp; with&nbsp; the&nbsp; added advantage&nbsp; of&nbsp; greater&nbsp; visibility&nbsp; of&nbsp; bands&nbsp; of&nbsp; fibrosis&nbsp; on&nbsp; both non contrast&nbsp; and&nbsp; contrast-enhanced&nbsp; sequences&nbsp; [28].However,&nbsp; its &nbsp;utility&nbsp; for detecting&nbsp; early&nbsp; liver&nbsp; fibrosis&nbsp; remains&nbsp; limited&nbsp; because these&nbsp; changes do not&nbsp; occur&nbsp; until fibrosis has progressed to a very advanced stage.</p>
<p>A number of advanced MRI techniques have been assessed for detecting liver fibrosis. Diffusion-weighted imaging has been used to assess the restriction&nbsp; of free water&nbsp; proton movement in the hepatic parenchyma as a&nbsp; marker of collagen&nbsp; deposition,&nbsp; the&nbsp; microscopic manifestation&nbsp; of&nbsp; liver&nbsp; fibrosis.&nbsp; A&nbsp; meta-analysis of&nbsp; studies on&nbsp; diffusion-weighted&nbsp; imaging&nbsp; for this&nbsp; application&nbsp; showed&nbsp; that&nbsp; diffusion-weighted&nbsp; imaging&nbsp; was most&nbsp; useful&nbsp; for detecting advanced fibrosis but had lower performance for detecting early fibrosis (sensitivity 77%, specificity 78%) [29]. &nbsp;</p>
<p>Additionally,&nbsp; questions&nbsp; about &nbsp;the&nbsp; optimal&nbsp; acquisition&nbsp; technique&nbsp; and&nbsp; image&nbsp; processing&nbsp; methodologies&nbsp; (apparent diffusion coefficient, intravoxel incoherent motion, etc) remain unresolved.MR perfusion techniques have been described and found to be relatively accurate for the diagnosis and staging of liver&nbsp; fibrosis [30].&nbsp; &nbsp;</p>
<p>However,&nbsp; like&nbsp; CT perfusion,&nbsp; these are dependent&nbsp; on&nbsp; details of&nbsp; the&nbsp; acquisition&nbsp; and&nbsp; processing techniques and can be quite laborious, so they are not broadly used in clinical practice. Hepatobiliary MR contrast agent (gadoxetate disodium)&nbsp; uptake has been described as a method for measuring liver &ldquo;function&rdquo; and has been found to correlate with hepatic fibrosis stage [31,32]. A variety of metrics of contrast agent uptake has been explored, but in general, this methodology has been found to be less accurate than MR elastography and has not been widely adopted.</p>
<p><strong>US Abdomen</strong></p>
<p>Conventional US can be used in the assessment of liver fibrosis for detecting ultrastructural changes such as surfacenodularity, coarsened echotexture, and lobar atrophy/hypertrophy, similar to conventional CT and MRI [24,33,34].</p>
<p>US&nbsp; has an&nbsp; advantage&nbsp; in&nbsp; that&nbsp; high&nbsp; spatial&nbsp; resolution&nbsp; imaging&nbsp; of&nbsp; the&nbsp; liver&nbsp; surface can&nbsp; be&nbsp; performed&nbsp; with&nbsp; highfrequency transducers, which can demonstrate subtle surface nodularity</p>
<p><strong>US Abdomen with IV Contrast</strong></p>
<p>US abdomen with IV contrast or CEUS has been assessed for evaluation of liver fibrosis. Similar to CT and MRIperfusion techniques,&nbsp;&nbsp; CEUS&nbsp;&nbsp; uses contrast&nbsp;&nbsp; media&nbsp;&nbsp; transit&nbsp;&nbsp; characteristics to&nbsp;&nbsp; make&nbsp;&nbsp; deductions&nbsp;&nbsp; about&nbsp;&nbsp; liverhemodynamics that relate to the presence and severity of liver fibrosis [35,36]. Although early data on the utility of CEUS for assessing liver fibrosis and portal hypertension are promising, this is an area of ongoing research at thistime.</p>
<p><strong>US Shear Wave Elastography Abdomen</strong></p>
<p>SWE extends the capabilities of conventional US by assessing tissue deformation in response to high-intensity USpulses and&nbsp; the&nbsp; generation&nbsp; of&nbsp; shear&nbsp; waves,&nbsp; from&nbsp; which&nbsp; deductions&nbsp; about&nbsp; tissue stiffness&nbsp; can&nbsp; be&nbsp; made.&nbsp; SWE techniques allow simultaneous visualization&nbsp; of&nbsp; the&nbsp; liver&nbsp; to&nbsp; direct&nbsp; measurements&nbsp; to&nbsp; a&nbsp; representative&nbsp; region&nbsp; of&nbsp; parenchyma. Two-dimensional SWE allows for interrogation of large or distributed regions of the liver in order to obtain&nbsp; representative stiffness measures across the&nbsp; liver.&nbsp; As with&nbsp; MR&nbsp; elastography,&nbsp; sonographic&nbsp; assessments of liver&nbsp; stiffness can&nbsp; be&nbsp; confounded&nbsp; by&nbsp; parenchyma,&nbsp; edema,&nbsp; inflammation, cholestasis,&nbsp; and&nbsp; other&nbsp; factors [37,38]. Additionally, high-quality data can be difficult to obtain in obese patients. Although less sensitive for intermediatestages of fibrosis, SWE can provide an overall accurate assessment of hepatic fibrosis, with a reported area underthe receiver operating characteristic curves of 0.88 for predicting advanced stages of fibrosis (stage &ge;2) and 0.91 for cirrhosis (stage 4) in a meta-analysis of 21 studies (2,691 patients with chronic hepatitis B and C infections) [39].</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><strong>US Duplex Doppler Abdomen</strong></p>
<p>Doppler US can demonstrate hemodynamic alterations indicative of portal hypertension, though these are typicallyonly&nbsp; seen&nbsp; in&nbsp; the&nbsp; setting&nbsp; of&nbsp; long-standing&nbsp; fibrosis&nbsp; or&nbsp; cirrhosis [40,41].&nbsp; Though only&nbsp; moderately&nbsp; sensitive foradvanced fibrosis/cirrhosis, it&nbsp;&nbsp; can be used for initial assessment of patients with suspected long-standing chronicliver disease in combination with conventional grayscale US</p>

<p><strong>References</strong></p>
<ol>
    <li>Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med2006;144:705-14.</li>
    <li>Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology2010;138:513-21, 21 e1-6.</li>
    <li>Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the&nbsp; development&nbsp; of&nbsp; hepatocellular&nbsp; carcinoma:&nbsp; a&nbsp; meta-analysis&nbsp; of&nbsp; observational&nbsp; studies.&nbsp; Ann&nbsp; Intern&nbsp; Med2013;158:329-37.</li>
    <li>Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol2019;70:151-71.</li>
    <li>Asrani SK,&nbsp; Larson&nbsp; JJ,&nbsp; Yawn&nbsp; B,&nbsp; Therneau&nbsp; TM,&nbsp; Kim&nbsp; WR.&nbsp; Underestimation&nbsp; of&nbsp; liver-related&nbsp; mortality&nbsp; in&nbsp; the&nbsp; United States. Gastroenterology2013;145:375-82 e1-2.</li>
    <li>Tapper EB,&nbsp; Parikh&nbsp; ND.&nbsp; Mortality&nbsp; due&nbsp; to&nbsp; cirrhosis&nbsp; and&nbsp; liver&nbsp; cancer&nbsp; in&nbsp; the&nbsp; United&nbsp; States,&nbsp; 1999-2016: observational study. BMJ2018;362:k2817.</li>
    <li>Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol2002;97:2614-8.</li>
    <li>Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver D. Liver biopsy. Hepatology2009;49:1017-44</li>
</ol>
<p>.9.&nbsp;&nbsp;&nbsp; Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol2006;44:462-74.</p>
<ol start="10">
    <li>Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology2018;68:723-50.</li>
    <li>Heimbach JK,&nbsp; Kulik&nbsp; LM,&nbsp; Finn&nbsp; RS,&nbsp; et&nbsp; al.&nbsp; AASLD&nbsp; guidelines&nbsp; for&nbsp; the&nbsp; treatment &nbsp;of&nbsp; hepatocellular&nbsp; carcinoma.&nbsp; Hepatology2018;67:358-80.</li>
    <li>Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology2011;53:1020-2.</li>
    <li>Omata M,&nbsp; Cheng&nbsp; AL,&nbsp; Kokudo&nbsp; N,&nbsp; et&nbsp; al.&nbsp; Asia-Pacific&nbsp; clinical&nbsp; practice&nbsp; guidelines&nbsp; on&nbsp; the&nbsp; management&nbsp; of&nbsp; hepatocellular carcinoma: a 2017 update. Hepatol Int2017;11:317-70.</li>
    <li>Jang HJ, Kim TK, Wilson SR. Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol2009;72:418-24.</li>
    <li>Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology1989;172:389-92.</li>
    <li>Simonovsky V.&nbsp; The&nbsp; diagnosis&nbsp; of&nbsp; cirrhosis&nbsp; by&nbsp; high&nbsp; resolution&nbsp; ultrasound&nbsp; of&nbsp; the&nbsp; liver&nbsp; surface.&nbsp; Br&nbsp; J&nbsp; Radiol1999;72:29-34.</li>
    <li>Torres WE,&nbsp; Whitmire&nbsp; LF,&nbsp; Gedgaudas-McClees&nbsp; K,&nbsp; Bernardino&nbsp; ME.&nbsp; Computed&nbsp; tomography&nbsp; of&nbsp; hepatic&nbsp; morphologic changes in cirrhosis of the liver. J Comput Assist Tomogr1986;10:47-50.</li>
    <li>Ito K, Mitchell DG, Kim MJ, Awaya H, Koike S, Matsunaga N. Right posterior hepatic notch sign: a simple diagnostic MR finding of cirrhosis. J Magn Reson Imaging2003;18:561-6.</li>
    <li>Pickhardt PJ, Malecki K, Kloke J, Lubner MG. Accuracy of Liver Surface Nodularity Quantification on MDCT as a Noninvasive Biomarker for Staging Hepatic Fibrosis. AJR Am J Roentgenol2016;207:1194-99.</li>
    <li>Smith AD,&nbsp; Zand&nbsp; KA,&nbsp; Florez&nbsp; E,&nbsp; et&nbsp; al.&nbsp; Liver&nbsp; Surface&nbsp; Nodularity&nbsp; Score&nbsp; Allows&nbsp; Prediction&nbsp; of&nbsp; Cirrhosis&nbsp; Decompensation and Death. Radiology2017;283:711-22.</li>
    <li>Zissen MH, Wang ZJ, Yee J, Aslam R, Monto A, Yeh BM. Contrast-enhanced CT quantification of the hepatic fractional extracellular&nbsp;&nbsp; space:&nbsp;&nbsp; correlation&nbsp;&nbsp; with&nbsp;&nbsp; diffuse&nbsp;&nbsp; liver&nbsp;&nbsp; disease&nbsp;&nbsp; severity.&nbsp;&nbsp; AJR&nbsp;&nbsp; Am&nbsp;&nbsp; J&nbsp;&nbsp; Roentgenol2013;201:1204-10.</li>
    <li>Varenika V, Fu Y, Maher JJ, et al. Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT.Radiology2013;266:151-8.</li>
    <li>Bonekamp D, Bonekamp S, Geiger B, Kamel IR. An elevated arterial enhancement fraction is associated with clinical and imaging indices of liver fibrosis and cirrhosis. J Comput Assist Tomogr2012;36:681-9.</li>
    <li>Bonekamp S,&nbsp; Kamel&nbsp; I,&nbsp; Solga&nbsp; S,&nbsp; Clark&nbsp; J.&nbsp; Can&nbsp; imaging&nbsp; modalities&nbsp; diagnose&nbsp; and&nbsp; stage&nbsp; hepatic&nbsp; fibrosis&nbsp; and&nbsp; cirrhosis accurately? J Hepatol2009;50:17-35.</li>
    <li>Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol2015;13:440-51 e6.</li>
    <li>Chou CT, Chen RC, Wu WP, Lin PY, Chen YL. Prospective Comparison of the Diagnostic Performance of Magnetic Resonance&nbsp; Elastography&nbsp; with&nbsp; Acoustic&nbsp; Radiation&nbsp; Force&nbsp; Impulse&nbsp; Elastography&nbsp; for&nbsp; Pre-operative Staging of Hepatic Fibrosis in Patients with Hepatocellular Carcinoma. Ultrasound Med Biol2017;43:2783-90.</li>
    <li>Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging2013;37:544-55.</li>
    <li>Martin DR,&nbsp; Lauenstein&nbsp; T,&nbsp; Kalb&nbsp; B,&nbsp; et&nbsp; al.&nbsp; Liver&nbsp; MRI&nbsp; and&nbsp; histological&nbsp; correlates&nbsp; in&nbsp; chronic&nbsp; liver&nbsp; disease&nbsp; on&nbsp; multiphase gadolinium-enhanced 3D gradient echo imaging. J Magn Reson Imaging2012;36:422-9.</li>
    <li>Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology2012;56:239-47.</li>
    <li>Chen BB,&nbsp; Hsu&nbsp; CY,&nbsp; Yu&nbsp; CW,&nbsp; et&nbsp; al.&nbsp; Dynamic&nbsp; contrast-enhanced&nbsp; magnetic&nbsp; resonance&nbsp; imaging&nbsp; with&nbsp; Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol2012;22:171-80.</li>
    <li>Choi YR, Lee JM, Yoon JH, Han JK, Choi BI. Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic&nbsp; resonance&nbsp; imaging&nbsp; for&nbsp; the&nbsp; evaluation&nbsp; of&nbsp; hepatic&nbsp; fibrosis.&nbsp; Invest&nbsp; Radiol2013;48:607-13.</li>
    <li>Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. Radiology2011;259:142-50.</li>
    <li>Colli A, Colucci A, Paggi S, et al. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol2005;11:7318-22.</li>
    <li>Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med2002;21:1023-32; quiz 33-4.</li>
    <li>Kim G,&nbsp; Shim&nbsp; KY,&nbsp; Baik&nbsp; SK.&nbsp; Diagnostic&nbsp; Accuracy&nbsp; of&nbsp; Hepatic&nbsp; Vein&nbsp; Arrival&nbsp; Time&nbsp; Performed&nbsp; with&nbsp; Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut Liver2017;11:93-101.</li>
    <li>Nasr P, Hilliges A, Thorelius L, Kechagias S, Ekstedt M. Contrast-enhanced ultrasonography could be a non-invasive method&nbsp; for&nbsp; differentiating&nbsp; none&nbsp; or&nbsp; mild &nbsp;from&nbsp; severe&nbsp; fibrosis&nbsp; in&nbsp; patients&nbsp; with&nbsp; biopsy&nbsp; proven&nbsp; non-alcoholic fatty liver disease. Scand J Gastroenterol2016;51:1126-32.</li>
    <li>Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology2008;47:380-4.</li>
    <li>Millonig G,&nbsp; Reimann&nbsp; FM,&nbsp; Friedrich&nbsp; S,&nbsp; et&nbsp; al.&nbsp; Extrahepatic&nbsp; cholestasis&nbsp; increases&nbsp; liver&nbsp; stiffness&nbsp; (FibroScan)&nbsp; irrespective of fibrosis. Hepatology2008;48:1718-23.</li>
    <li>Hu X, Qiu L, Liu D, Qian L. Acoustic Radiation Force Impulse (ARFI) Elastography for noninvasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason2017;19:23-31.</li>
    <li>Kawanaka H, Kinjo N, Anegawa G, et al. Abnormality of the hepatic vein waveforms in cirrhotic patients with portal hypertension and its prognostic implications. J Gastroenterol Hepatol2008;23:e129-36.</li>
    <li>Oguzkurt L, Yildirim T, Torun D, Tercan F, Kizilkilic O, Niron EA. Hepatic vein Doppler waveform in patients with diffuse fatty infiltration of the liver. Eur J Radiol2005;54:253-7.</li>
    <li>Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology2009;137:26-9.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&nbsp; Appropriateness&nbsp; Criteria&reg;:&nbsp; Liver&nbsp; Lesion&nbsp; &mdash; Initial&nbsp; Characterization.&nbsp; Available at: https://acsearch.acr.org/docs/69472/Narrative/. Accessed November 29, 2019.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; Liver&nbsp; Imaging&nbsp; Reporting&nbsp; and&nbsp; Data &nbsp;System&nbsp; (LI-RADS).&nbsp;&nbsp;&nbsp; Available&nbsp; at:&nbsp; http://www.acr.org/quality-safety/resources/LIRADS. Accessed November 29, 2019.</li>
    <li>Luca A, Caruso S, Milazzo M, et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol2010;20:898-907.</li>
    <li>Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol2011;80:310-5.</li>
    <li>Inoue T,&nbsp; Kudo&nbsp; M,&nbsp; Komuta&nbsp; M,&nbsp; et&nbsp; al.&nbsp; Assessment&nbsp; of&nbsp; Gd-EOB-DTPA-enhanced&nbsp; MRI&nbsp; for&nbsp; HCC&nbsp; and&nbsp; dysplastic&nbsp; nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol2012;47:1036-47.</li>
    <li>Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol2011;9:161-7</li>
</ol>
<p>.49.&nbsp; Khan&nbsp; MA,&nbsp; Combs&nbsp; CS,&nbsp; Brunt&nbsp; EM,&nbsp; et&nbsp; al.&nbsp; Positron&nbsp; emission&nbsp; tomography&nbsp; scanning&nbsp; in&nbsp; the&nbsp; evaluation&nbsp; of&nbsp; hepatocellular carcinoma. J Hepatol2000;32:792-7.</p>
<ol start="50">
    <li>Ronot M, Vilgrain V. Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol2014;38:681-8.</li>
    <li>Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology2008;47:97-104.</li>
    <li>Marrero JA,&nbsp; Hussain&nbsp; HK,&nbsp; Nghiem&nbsp; HV,&nbsp; Umar&nbsp; R,&nbsp; Fontana&nbsp; RJ,&nbsp; Lok&nbsp; AS.&nbsp; Improving&nbsp; the&nbsp; prediction&nbsp; of&nbsp; hepatocellular&nbsp;&nbsp; carcinoma&nbsp;&nbsp; in&nbsp;&nbsp; cirrhotic&nbsp;&nbsp; patients&nbsp;&nbsp; with&nbsp;&nbsp; an &nbsp;&nbsp;arterially-enhancing&nbsp;&nbsp; liver&nbsp;&nbsp; mass.&nbsp;&nbsp; Liver&nbsp;&nbsp; Transpl2005;11:281-9.</li>
    <li>Ooka Y, Kanai F, Okabe S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging2013;31:748-54.</li>
    <li>Rhee H,&nbsp; Kim&nbsp; MJ,&nbsp; Park&nbsp; MS,&nbsp; Kim&nbsp; KA.&nbsp; Differentiation&nbsp; of&nbsp; early&nbsp; hepatocellular&nbsp; carcinoma&nbsp; from&nbsp; benign&nbsp; hepatocellular nodules on gadoxetic acid-enhanced MRI. Br J Radiol2012;85:e837-44.</li>
    <li>Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology2010;78 Suppl 1:180-8.</li>
    <li>Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis. Liver Transpl2017;23:1505-18.</li>
    <li>Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging&nbsp; with&nbsp; gadoxetate&nbsp; disodium:&nbsp; examination&nbsp; recovery&nbsp; with&nbsp; a&nbsp; multiple&nbsp; arterial&nbsp; phase&nbsp; acquisition.&nbsp; Radiology2014;271:426-34.</li>
    <li>Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol2018;210:1266-72.</li>
    <li>Marks RM,&nbsp; Ryan&nbsp; A,&nbsp; Heba&nbsp; ER,&nbsp; et&nbsp; al.&nbsp; Diagnostic&nbsp; per-patient&nbsp; accuracy&nbsp; of&nbsp; an&nbsp; abbreviated&nbsp; hepatobiliary&nbsp; phase&nbsp; gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol2015;204:527-35.</li>
    <li>Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated&nbsp; MRI&nbsp; protocol&nbsp; combining&nbsp; diffusion-weighted&nbsp; and&nbsp; T1-weighted&nbsp; imaging&nbsp; at&nbsp; the&nbsp; delayed&nbsp; phase post gadoxetic acid. Abdom Radiol (NY)2017;42:179-90.</li>
    <li>Tillman BG, Gorman JD, Hru JM, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol2018;73:485-93.</li>
    <li>2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol2019;20:1042-113.</li>
    <li>Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer2015;4:85-95.</li>
    <li>Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol1997;123:357-60.</li>
    <li>Choi DT, Kum HC, Park S, et al. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol2019;17:976-87 e4.</li>
    <li>Singal AG, Mittal S, Yerokun OA, et al. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med2017;130:1099-106 e1.</li>
    <li>D'Onofrio M,&nbsp; Faccioli&nbsp; N,&nbsp; Zamboni&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Focal&nbsp; liver&nbsp; lesions&nbsp; in&nbsp; cirrhosis:&nbsp; value&nbsp; of &nbsp;contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels. Radiol Med2008;113:978-91.</li>
    <li>Wang JH, Lu SN, Hung CH, et al. Small hepatic nodules (&lt; or =2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int2006;26:928-34.</li>
    <li>Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol2013;39:187-210.</li>
    <li>Gallotti A, D'Onofrio M, Romanini L, Cantisani V, Pozzi Mucelli R. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging of solid focal liver lesions. Eur J Radiol2012;81:451-5.</li>
    <li>Park H, Park JY, Kim DY, et al. Characterization of focal liver masses using acoustic radiation force impulse elastography. World J Gastroenterol2013;19:219-26.</li>
    <li>Doyle DJ, O'Malley ME, Jang HJ, Jhaveri K. Value of the unenhanced phase for detection of hepatocellular carcinomas 3&nbsp; cm&nbsp; or&nbsp; less&nbsp; when&nbsp; performing&nbsp; multiphase&nbsp; computed&nbsp; tomography&nbsp; in&nbsp; patients&nbsp; with&nbsp; cirrhosis.&nbsp; J&nbsp; Comput Assist Tomogr2007;31:86-92.</li>
    <li>Iannaccone R,&nbsp; Laghi&nbsp; A,&nbsp; Catalano&nbsp; C,&nbsp; et&nbsp; al.&nbsp; Hepatocellular&nbsp; carcinoma:&nbsp; role&nbsp; of&nbsp; unenhanced&nbsp; and&nbsp; delayed&nbsp; phase&nbsp; multi-detector row helical CT in patients with cirrhosis. Radiology2005;234:460-7.</li>
    <li>Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635-54.</li>
    <li>European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol2012;56:908-43.</li>
    <li>Wang XY, Chen D, Zhang XS, Chen ZF, Hu AB. Value of (1)(8)F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma&nbsp; after&nbsp; hepatectomy&nbsp; or&nbsp; radiofrequency&nbsp; ablation:&nbsp; a&nbsp; comparative&nbsp; study&nbsp; with&nbsp; contrast-enhanced ultrasound. J Dig Dis2013;14:433-8.</li>
    <li>NCCN Clinical&nbsp; Practice&nbsp; Guidelines&nbsp; in&nbsp; Oncology.&nbsp; Hepatobiliary&nbsp; Cancers.&nbsp; Version&nbsp; 1.2018.&nbsp;&nbsp;&nbsp; Available&nbsp; at:&nbsp; https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed November 29, 2019.</li>
    <li>Roberts LR,&nbsp; Sirlin&nbsp; CB,&nbsp; Zaiem&nbsp; F,&nbsp; et&nbsp; al.&nbsp; Imaging&nbsp; for&nbsp; the&nbsp; diagnosis&nbsp; of&nbsp; hepatocellular&nbsp; carcinoma:&nbsp; A&nbsp; systematic&nbsp; review and meta-analysis. Hepatology2018;67:401-21.</li>
    <li>Jiang T, Zhao Q, Huang M, Sun J, Tian G. Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following&nbsp; Transarterial&nbsp; Chemoembolization:&nbsp; Is&nbsp; It&nbsp; Helpful&nbsp; for&nbsp; Tumor&nbsp; Response?&nbsp; Biomed&nbsp; Res&nbsp; Int2018;2018:8632069.</li>
    <li>Cao J,&nbsp; Dong&nbsp; Y,&nbsp; Mao&nbsp; F,&nbsp; Wang&nbsp; W.&nbsp; Dynamic&nbsp; Three-Dimensional&nbsp; Contrast-Enhanced&nbsp; Ultrasound&nbsp; to&nbsp; Predict&nbsp; Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. Biomed Res Int2018;2018:6469703.</li>
    <li>Hu J, Bhayana D, Burak KW, Wilson SR. Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. Abdom Radiol (NY)2019:[E-pub ahead of print].</li>
    <li>Zhang P, Zhou P, Tian SM, Qian Y, Deng J, Zhang L. Application of acoustic radiation force impulse imaging for the evaluation of focal liver lesion elasticity. Hepatobiliary Pancreat Dis Int2013;12:165-70.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&nbsp; Appropriateness&nbsp; Criteria&reg;&nbsp; Radiation&nbsp; Dose&nbsp; Assessment&nbsp; Introduction.&nbsp; Available&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf. Accessed November 29, 2019</li>
</ol>
<p>&nbsp;</p>
</body>
</html>